PTGX · Protagonist Therapeutics

The thesis

Protagonist Therapeutics is modestly more likely than not to beat the S&P 500 over the next three months. It holds $834.6 million in cash and marketable securities (company release, 5 November 2026) and earns royalties on two approved drugs sold by partners: Johnson & Johnson's (J&J) ICOTYDE and Takeda's MIMRYLO. J&J's fourth-quarter report, expected around January 2027, and Protagonist's own fourth-quarter report, expected around February 2027, show whether royalties are arriving in meaningful amounts.

No royalty income has yet appeared in Protagonist's reported results. Third-quarter license and collaboration revenue of $274.4 million included $266.6 million of Takeda payment recognition and $7.8 million of development services and other revenue (company release, 5 November 2026).

The shares closed at $134.38 on 12 November 2026, down 13.4% over three months, while H.C. Wainwright raised its target to $221 from $170 on 6 November 2026. Price targets are rising while the share price drifts lower. Partner sales figures are the evidence that would close that gap.

Bullish and bearish views on Protagonist Therapeutics, Inc.

The bull case on Protagonist Therapeutics, Inc. (PTGX), in brief: the cash balance is large. The bear case: no royalty line has appeared yet.

Bull case

• The cash balance is large. Cash and marketable securities were $834.6 million at 30 September 2026, and the $275 million of Takeda payments arrived in October 2026 (company release, 5 November 2026). Third-quarter research spending was $41.3 million.
• The royalty rates are high. The 5 November 2026 release puts MIMRYLO royalties at 14–29%, about 21% on average at $1.5 billion of annual sales. ICOTYDE royalties run 6–10%, about 7.25% on average at $4 billion of annual sales.
• ICOTYDE is reaching more markets. The company reported psoriasis approvals in China, Japan and the European Union during the third quarter of 2026. Up to $580 million of ICOTYDE milestones and up to $875 million of MIMRYLO milestones remain available (release, 5 November 2026).
• Analysts raised targets after the report. H.C. Wainwright's target is $221 as of 6 November 2026, and Wedbush maintained its buy rating on 10 November 2026. MarketBeat puts the consensus target at $166.67 across one strong-buy, 15 buy and one hold rating as of 6 November 2026. Leerink Partners started coverage at $190 on 12 October 2026.
• The buyback has started. The quarterly report on Form 10-Q, filed 6 November 2026, shows 40,560 shares repurchased for $5.8 million under the $300 million authorization approved on 8 September 2026. That left $294.2 million authorized at 30 September 2026 (StockTitan summary of the filing).
• Company drug candidates have dated trial starts. The company plans a Phase 2b psoriasis study of PN-881, its oral IL-17 antagonist, in early 2027. It plans a Phase 1 study of PN-8047, an oral polycythemia vera candidate, in the first quarter of 2027.

Bear case

• No royalty line has appeared yet. The second-quarter Form 10-Q, filed 5 August 2026, recognized no royalty revenue in ICOTYDE's first full quarter of US sales. In the third quarter, only $7.8 million of revenue came from sources other than the Takeda recognition, and the company attributed it to development services and other revenue.
• Partner sales are not reported separately. The 5 November 2026 release gives no ICOTYDE or MIMRYLO sales figure. J&J's 13 October 2026 release credits "new products within Other Immunology" and gives no standalone ICOTYDE number.
• Headline earnings will not repeat automatically. Third-quarter net income of $220.0 million, or $3.07 per diluted share, rests on a one-time $275 million payment. The 10-Q says the company expects research and development expense to rise through the rest of 2026 as PN-881 moves toward Phase 2b.
• A rival drug posted strong trial results. Silence Therapeutics reported on 10 August 2026 that divesiran produced an 88% clinical response versus 19% for placebo in polycythemia vera, MIMRYLO's approved disease.
• Executives sold into strength. SEC Form 4 filings show President and Chief Executive Officer Dinesh Patel sold 125,000 shares at an average of $145.92 between 8 September 2026 and 10 September 2026. Chief Financial Officer Asif Ali sold 58,629 shares at an average of $141.78 on 30 September 2026. Both sales ran under Rule 10b5-1 plans, which set sale terms in advance.

Price setup

The shares closed at $134.38 on 12 November 2026. That is 16.4% below the 52-week intraday high of $160.81 set on 19 August 2026 and well above the 52-week closing low of $79.73 on 29 January 2026. The three-month change is –13.4% from the 14 August 2026 close of $155.10.

The 50-day average of adjusted closes is $140.66, so the shares trade under it. The 200-day average is $119.03, below the price. The range since the third-quarter report has been narrow: closes of $135.26 on 5 November 2026, $132.04 on 6 November 2026 and $134.86 on 11 November 2026.

The kill line sits between the last close and the 200-day average. A close through it would put the shares under every level held since the approvals.

The price reflects both approvals and the Takeda payments, which were known before the 5 November 2026 report. It does not yet reflect a royalty figure, because none has been reported.

Catalysts ahead

• 16 November 2026: Fireside chat at the UBS Global Biopharma Conference, London. Management could comment on partner uptake and on repurchase activity after the first buyback shares in the quarterly filing.
• 17 November 2026: Fireside chat at the Jefferies Global Healthcare Conference, London. This is the last scheduled public management appearance before year-end results.
• ~20 January 2027 (est.): Johnson & Johnson fourth-quarter 2026 results. A standalone ICOTYDE sales figure would allow the royalty stream to be sized for the first time.
• ~26 February 2027 (est.): Protagonist fourth-quarter 2026 results. It is the first quarter with three full months of MIMRYLO sales and shows whether royalties appear without Takeda milestone recognition.

What would change the view

A daily close below $122.00, which would put the shares under the range held since the Takeda payments and the ICOTYDE approvals. A fourth-quarter 2026 Protagonist report showing negligible royalty revenue would also show the case failing.

The risks this note tracks, each with what would confirm it:

• Recurring royalty revenue fails to replace one-time Takeda recognition. Confirmed by: Protagonist's fourth-quarter 2026 report showing negligible royalties, or a partner report that lowers launch expectations.
• Divesiran competes with MIMRYLO in polycythemia vera. Confirmed by: further Silence Therapeutics clinical or regulatory progress, or physician and analyst commentary favoring divesiran.
• The repurchase authorization stays largely unused while executives keep selling. Confirmed by: the fourth-quarter report showing repurchases far below the $294.2 million remaining at 30 September 2026, alongside further Form 4 sales by executives.
• Rising development spending outpaces early royalties. Confirmed by: quarterly research expense climbing above the $41.3 million of the third quarter of 2026 while royalties stay immaterial in reported revenue.

What it trades with

The shares trade on partner news. J&J and Takeda earnings releases move them more than Protagonist's own milestone-heavy results do. Silence Therapeutics data on divesiran tends to move them in the opposite direction, because both drugs target polycythemia vera. Large immunology acquisitions, such as AbbVie's $10.9 billion agreement for Apogee reported by Benzinga on 22 June 2026, set the valuation comparisons used for oral and next-generation immunology assets. The shares also carry general biotech-sector risk.